ANPAC BIO-MEDICAL SCIENCE CO. news, videos and press releases
For more news please use our advanced search feature.
ANPAC BIO-MEDICAL SCIENCE CO. - More news...
ANPAC BIO-MEDICAL SCIENCE CO. - More news...
- AnPac Announces the Plan of US$5,000,000 Private Placement
- AnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food Market
- AnPac Announces Regaining Compliance with Nasdaq Listing Requirement
- AnPac Bio Announces Changes to the Board of Directors
- AnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022
- AnPac Bio Announces Plan to Implement ADS Ratio Change
- AnPac Bio Announces Board and Management Changes
- AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million
- AnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022
- AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal
- AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer
- AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees
- AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market
- AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022
- AnPac Bio Reports Fiscal Year 2021 Annual Financial Results
- AnPac Bio Regains Compliance with Market-Value-Of-Publicly Held Shares Requirement upon Transfer to The Nasdaq Capital Market
- Nasdaq Hearing Panel Grants AnPac Bio’s Request to Transfer Securities from The Nasdaq Global Market to The Nasdaq Capital Market
- AnPac Bio and New Investor Sign Equity Investment Totaling $15 Million
- AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member
- AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April
- AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
- AnPac Bio-Medical Sciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
- AnPac Bio’s Bio-Chip Subsidiary, Changwei System Technology Co., Ltd., Receives Independent Valuation and Approval from the Board to Explore Strategic Alternatives
- AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA
- Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume
- AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
- AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022
- Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
- AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%
- CORRECTION -- Anpac Bio, USA
